Cargando…
Debate: Does it matter how you lower blood pressure?
Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly h...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59601/ https://www.ncbi.nlm.nih.gov/pubmed/11714412 http://dx.doi.org/10.1186/cvm-1-2-069 |
_version_ | 1782120082545049600 |
---|---|
author | Alderman, Michael H |
author_facet | Alderman, Michael H |
author_sort | Alderman, Michael H |
collection | PubMed |
description | Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly half that expected. This suggested that adverse drug effects of diuretics and β-blockers might have detracted from their hypotensive effects. Trials with newer antihypertensive classes have revealed superior effects on outcomes associated with converting enzyme inhibitor use, and that α-blockers are less cardioprotective than diuretics. These studies establish that simple blood pressure reduction is an inadequate guide to therapy. The challenge now will be to determine the optimal therapy for each hypertensive patient. |
format | Text |
id | pubmed-59601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-596012001-11-06 Debate: Does it matter how you lower blood pressure? Alderman, Michael H Curr Control Trials Cardiovasc Med Commentary Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given difference in blood pressure was achieved, the results for myocardial infarction were roughly half that expected. This suggested that adverse drug effects of diuretics and β-blockers might have detracted from their hypotensive effects. Trials with newer antihypertensive classes have revealed superior effects on outcomes associated with converting enzyme inhibitor use, and that α-blockers are less cardioprotective than diuretics. These studies establish that simple blood pressure reduction is an inadequate guide to therapy. The challenge now will be to determine the optimal therapy for each hypertensive patient. BioMed Central 2000 2000-08-17 /pmc/articles/PMC59601/ /pubmed/11714412 http://dx.doi.org/10.1186/cvm-1-2-069 Text en Copyright © 2000 Current Controlled Trials Ltd |
spellingShingle | Commentary Alderman, Michael H Debate: Does it matter how you lower blood pressure? |
title | Debate: Does it matter how you lower blood pressure? |
title_full | Debate: Does it matter how you lower blood pressure? |
title_fullStr | Debate: Does it matter how you lower blood pressure? |
title_full_unstemmed | Debate: Does it matter how you lower blood pressure? |
title_short | Debate: Does it matter how you lower blood pressure? |
title_sort | debate: does it matter how you lower blood pressure? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59601/ https://www.ncbi.nlm.nih.gov/pubmed/11714412 http://dx.doi.org/10.1186/cvm-1-2-069 |
work_keys_str_mv | AT aldermanmichaelh debatedoesitmatterhowyoulowerbloodpressure |